Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. Among authors: di giambenedetto s. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.
De Luca A, Baldini F, Cingolani A, Di Giambenedetto S, Zaccarelli M, Tozzi V, Ammassari A, Murri R, Antinori A. De Luca A, et al. Among authors: di giambenedetto s. AIDS. 2000 Jul 28;14(11):1655-6. doi: 10.1097/00002030-200007280-00022. AIDS. 2000. PMID: 10983653 No abstract available.
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy.
Gillini LA, Cingolani A, Murri R, De Luca A, Di Giambenedetto S, Wu A, Cauda R, Chaisson RE. Gillini LA, et al. Among authors: di giambenedetto s. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):546-7. doi: 10.1097/00126334-200204150-00018. J Acquir Immune Defic Syndr. 2002. PMID: 11981374 No abstract available.
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
Zaccarelli M, Perno CF, Forbici F, Cingolani A, Liuzzi G, Bertoli A, Trotta MP, Bellocchi MC, Di Giambenedetto S, Tozzi V, Gori C, D'Arrigo R, De Longis P, Noto P, Girardi E, De Luca A, Antinori A. Zaccarelli M, et al. Among authors: di giambenedetto s. Antivir Ther. 2003 Feb;8(1):51-6. Antivir Ther. 2003. PMID: 12713064
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.
De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, Bertoli A, Liuzzi G, Narciso P, Murri R, Ammassari A, Perno CF, Antinori A. De Luca A, et al. Among authors: di giambenedetto s. J Infect Dis. 2003 Jun 15;187(12):1934-43. doi: 10.1086/375355. Epub 2003 May 22. J Infect Dis. 2003. PMID: 12792870 Clinical Trial.
289 results